Dr. Dawit Gebremichael Aregawi, MD

Dr. Aregawi practices at Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State.

Dr. Aregawi's NPI, 1962424960, was assigned on July 25, 2006. Dr. Aregawi holds Pennsylvania license MD453085.

Dr. Aregawi's primary practice is Penn State Health Milton S. Hershey Medical Center, at 500 University Drive, Hershey, PA 17033 in Dauphin County. The practice phone is (717) 531-8521.

Dr. Aregawi's primary practice is Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State. Dr. Aregawi is also affiliated with Penn State Health Holy Spirit Medical Center. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Aregawi to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aregawi practices, 7 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Aregawi's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dmand AI has Dr. Aregawi's licenses on file in 2 states: Pennsylvania and Virginia.

CMS data shows 190 Medicare services from Dr. Aregawi across 3 procedure codes in 2024, for 79 Medicare patients. Medicare paid $13,382 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Dr. Aregawi in 2024. The largest group is 65 to 74, with 36 patients. 62% of them have high blood pressure, and 61% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aregawi's median patient age at 66, with 44% women.

In 2024, Dr. Aregawi wrote 442 Medicare Part D claims for 81 patients. 98% of them were for generic drugs. CMS names the drug for 355 of them, across 12 drugs with 11 or more claims each, at $95,054 in total drug cost. In 2023, CMS named 288 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Aregawi for performance year 2024, reported as part of a group. Dr. Aregawi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Aregawi as offering telehealth.

Dmand AI links 14 papers to Dr. Aregawi, published from 2015 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Glioblastoma, Brain Neoplasms and Cell Line, Tumor. Dr. Aregawi's most frequent co-authors are Michael J. Glantz, MD, Brad E. Zacharia and Elias B. Rizk, MD.

Dmand AI links Dr. Aregawi to 5 clinical trials, 3 of them phase 3 studies. Conditions studied include Glioblastoma, Astrocytoma and Carcinoma, Renal Cell. Open Payments lists research payments to Dr. Aregawi that name 1 trial.

CMS Open Payments shows 18 general payments to Dr. Aregawi from 4 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Novocure Inc. paid the most, $1,183. It also lists 1 research payment totaling $1,357 in 2016, naming 1 clinical trial.